Vicore Pharma Holding AB (STU:6Y4) EPS (Basic) : €-0.10 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB EPS (Basic)?

Vicore Pharma Holding AB's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was €-0.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.10.

Vicore Pharma Holding AB's EPS (Diluted) for the three months ended in Dec. 2024 was €-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.10.

Vicore Pharma Holding AB's EPS without NRI for the three months ended in Dec. 2024 was €-0.04. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.10.

During the past 3 years, the average EPS without NRI Growth Rate was 33.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Vicore Pharma Holding AB's highest 3-Year average EPS without NRI Growth Rate was 33.10% per year. The lowest was -65.80% per year. And the median was -33.40% per year.

Vicore Pharma Holding AB EPS (Basic) Historical Data

The historical data trend for Vicore Pharma Holding AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB EPS (Basic) Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-0.26

-0.40

-0.35

-0.28

-0.11

Vicore Pharma Holding AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.09	0.02	-0.04	-0.05	-0.04

Vicore Pharma Holding AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Vicore Pharma Holding AB's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-14.66	-	0)	/	137.738
	=	-0.11

Vicore Pharma Holding AB's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-7.309	-	0)	/	216.053
	=	-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.10

Vicore Pharma Holding AB (STU:6Y4) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Vicore Pharma Holding AB EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

VICO:Sweden 6Y4:Germany

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines